BiliRoo: New Baby Carrier Offers Safe, Low-Cost Jaundice Treatment

A new, low-cost medical device offers a potentially life-saving solution for treating neonatal jaundice, particularly in resource-limited settings. Known as BiliRoo, the device utilizes filtered sunlight to provide phototherapy while simultaneously promoting crucial skin-to-skin contact between parent and infant – a practice known as kangaroo care.

Neonatal jaundice, a yellowing of the skin and eyes, affects approximately 60 percent of newborns and 80 percent of premature infants. It occurs when bilirubin, a yellow pigment produced during normal red blood cell breakdown, accumulates faster than a baby’s body can process it. While typically benign, severe jaundice can lead to brain damage and, tragically, is ranked among the top 10 causes of neonatal death globally, with an estimated 100,000 deaths annually.

Currently, treatment in hospitals often involves placing infants under electric blue lamps to help break down bilirubin. However, access to this technology is limited in many parts of the world, forcing families to rely on sunlight exposure – a practice that carries risks. While the blue wavelengths in sunlight can be therapeutic, the ultraviolet rays can damage a baby’s delicate skin and eyes.

BiliRoo, developed by University of Michigan medical student Daniel John, aims to mitigate these risks. The device consists of a baby carrier incorporating a transparent panel that filters out harmful ultraviolet radiation while allowing therapeutic blue light to pass through. “It’s low cost, easy-to-use, simple and non-electric,” John explained. The device is designed to be similar to standard kangaroo care slings, making it readily adaptable for existing care practices.

The inspiration for BiliRoo stems from John’s childhood experiences in Nepal, where frequent power outages disrupted hospital operations. Witnessing the challenges faced by his pediatrician father and engineer mother fueled his desire to create accessible medical technologies. He identified neonatal jaundice as a pressing need after consulting with physicians in Nepal and sub-Saharan Africa.

Research has demonstrated the effectiveness of filtered sunlight therapy. Studies in Nigeria, led by developmental pediatrician Bolajoko Olusanya, have shown that babies treated with filtered sunlight in tents and greenhouses experienced comparable bilirubin level reductions to those receiving standard phototherapy. However, widespread implementation has been hampered by logistical challenges and the need for extensive training of healthcare workers.

BiliRoo seeks to overcome these hurdles by delivering therapy directly to parents, enabling treatment within the home environment. The design allows for therapeutic light exposure even when the carrier is tilted at various angles, addressing a key limitation of previous filtered sunlight approaches. Initial testing in a university courtyard demonstrated that the sling consistently captured sufficient blue light for phototherapy while effectively blocking ultraviolet radiation.

While early results are promising, several questions remain. The intermittent nature of sunlight – due to cloud cover or indoor use – raises concerns about consistent therapeutic light delivery. The potential for overheating or dehydration from prolonged sun exposure, even with UV filtration, requires careful consideration.

John is currently preparing for clinical trials in Ogbomoso, Nigeria, slated to begin later this year. The first batch of BiliRoos is being manufactured in Nepal. The device is also being refined with an additional filter section to cover the baby’s head.

Pediatric intensive care specialist Tina Slusher, who pioneered early trials of filtered sunlight therapy in Nigeria, expressed cautious optimism. “I think it’s going to be a good device,” she said. “There won’t be enough of the baby exposed to treat super-bad jaundice.” However, she believes it could be highly effective for mild to moderate cases.

BiliRoo represents a potentially significant advancement in neonatal care, offering a low-cost, accessible, and parent-centered approach to treating jaundice in settings where traditional phototherapy is unavailable. Further research and clinical trials will be crucial to fully evaluate its efficacy and safety, and to determine its role in reducing the global burden of this preventable condition.